GILEAD SCIENCES SL

Dublin-based biotech Meta-Flux has secured €1.8 million in seed funding from senior executives at Pfizer, Merck, and Gilead Sciences to expand its AI-powered drug development platform.

Nurix Therapeutics announced plans to initiate pivotal trials for bexobrutideg in relapsed/refractory chronic lymphocytic leukemia patients in the second half of 2025, including both accelerated approval and confirmatory Phase 3 studies.

Expedition Therapeutics closed an oversubscribed $165 million Series A financing co-led by Sofinnova Investments and Novo Holdings to advance EXPD-101, a next-generation DPP1 inhibitor targeting neutrophilic inflammation in COPD.

Cartography Biosciences secured $67 million in Series B funding led by Pfizer Ventures to advance its lead T-cell engager CBI-1214 targeting colorectal cancer into Phase 1 trials.

Health Hope Pharma and Hanmi Pharm have granted Gilead Sciences exclusive global licensing rights to encequidar, a first-in-class P-glycoprotein inhibitor, specifically for virology applications.

Lupin Limited has received tentative FDA approval for its generic version of Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, targeting a significant HIV treatment market.

Zimbabwe has been chosen as one of only ten countries worldwide to introduce lenacapavir, a groundbreaking HIV prevention drug developed by Gilead Sciences that requires only twice-yearly injections.

The XBI biotech index experienced significant gains following regulatory developments and corporate announcements in the biotechnology sector.

Gilead Sciences has broken ground on a new 180,000 square foot Pharmaceutical Development and Manufacturing Technical Development Center at its Foster City headquarters as part of a $32 billion U.S. investment through 2030.

Pharming Group N.V. announced the appointment of Kenneth Lynard as Chief Financial Officer, effective October 1, 2025, following strong first half 2025 financial results.